The importance of osteoporosis was assessed on a 7-point Likert scale. The mean value was 6.23 (SD 1.28) for the patients and 6.22 (SD 0.83) for the physicians. Sixmonth adherence to once-monthly bisphosphonate was 90.6%. Better adherence was predicted for patients with higher levels of ...
Patient Satisfaction in Postmenopausal Women Treated with a Weekly Bisphosphonate Transitioned to Once-Monthly Ibandronate Objective: CURRENT, a large, open-label, 6-month, multicenter study, was designed to assess patient satisfaction levels and patient treatment preference af... Bonnick,SL,Silverman,....
bisphosphonate therapy do not maintain the same level of improvement in bone mineral density (BMD)[9],[10],[11]. Moreover, non-adherence with antiresorptive therapy has been reported frequently and it has been reported to result in a 16–50% increased risk of fracture[9],[10],[11],[...
However, poor adherence with bisphosphonate therapies for PMO results in a high incidence of otherwise preventable fractures. The chronicity of this condition requires long-term treatment, but fewer than one in two women remains on daily bisphosphonate therapy for 1 yr. A good way to reduce the ...
Ibandronate is a nitrogen-containing bisphosphonate that has been approved for once-monthly administration in women with post-menopausal osteoporosis. Animal data suggest that the efficacy of the drug is determined by the cumulative dose rather than the frequency of administration. After treatment for 1...
Once-monthly oral bisphosphonateOsteoporosisRheumatoid arthritisRisedronateA head-to-head comparison of once-monthly oral bisphosphonates minodronate (MIN) and risedronate (RIS) in patients with rheumatoid arthritis (RA) demonstrated that MIN has the same effect as RIS on increase in bone mineral ...
Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparisonBone mineral densityBone turnover markersMinodronateOnce-monthly oral bisphosphonateOsteoporosisRheumatoid arthritis...
invention provides a pharmaceutical composition for preventing or treating osteoporosis to be administered once a month, the pharmaceutical composition comprising a bisphosphonate derivative such as as risedronic acid (or its salt) or ibandronic acid (or its salt) and cholecalciferal in a high dose...
Oral ibandronate 150 mg is the first bisphosphonate approved for once-monthly treatment of postmenopausal osteoporosis. To investigate whether once-monthly ibandronate 150 mg increases lumbar spine and total hip bone mineral density (BMD) to the same degree as weekly alendronate 70 mg.#This was a ...
BisphosphonateChronic kidney diseaseeGFROnce-monthly risedronateRenal safetyLimited data are available on the safety and efficacy of anti-resorptive agents, particularly once-monthly bisphosphonates, for use in osteoporotic patients with chronic kidney disease (CKD). We conducted a post hoc analysis of ...